Skinbiotherapeutics Share Discussion Threads

[bobalot] 11/12/2017 15:51

Todays price is about as good as it gets as a buying opportunity into SkinBIO...strong buy....come and get it imo.

[elrico] 11/12/2017 14:26

Agree with my blue friend...no support now the IPO price has capitulated. Accumulate mode. Now where have we heard this before. :)

[bobalot] 11/12/2017 13:01

--- LETS GET IT RIGHT --- COMMERCIALISATION EARLY NEXT YEAR imo...with a major player in place already along with a major mass manufacturer already in the planning stages of production before human testing begins.

That all speaks of a high level of confidence for the tech....Dr. Cath has just been given an accolade of awards by her scientific peers for the work done...

THUS THE TECH WORKS AND WILL REACH A HUGE MARKET AT THE RIGHT PRICE.






elrico --------------- 11 Dec '17 - 14:26 - 1179 of 1180 1 0 (Filtered)
loungeact ===== 11 Dec '17 - 14:42 - 1180 of 1180 0 0 (Filtered)

BOTTOM FEEDERS CAN START TO ACCUMULATE...GREAT OPPORTUNITY..imo

[bobalot] 11/12/2017 13:00

The business is in the company of a leading edge researcher who wins awards for her work.

CEO Cath O'Neill named one of this years 50 female Movers and Shakers in the UK healthcare industry

CEO Cath O’Neill named one of this years 50 female Movers and Shakers in the UK healthcare industry by @BioBeatUK.

The annual report aims to celebrate exceptional female leaders and bioentrepreneurs who are driving innovative thinking within the industry.

Cath has been recognised for her outstanding research into skin health as well as spearheading the success of SkinBioTherapeutics
2nd November, 2017

[bobalot] 11/12/2017 12:59

HERE IS A KEYSTONE ANNOUNCEMENT ABOUT HEALTH AND SAFETY APPROVAL AND ANNOUNCES THE START OF HUMAN TESTING EARLY 2018...the testing only takes a month, so selling the stuff next year through a major brand name will happen imo.


SkinBiotix® platform passes additional external toxicity tests

SkinBiotix® platform passes additional external toxicity tests.
Scientific progress on track.

Manchester, UK – 9 November 2017 - SkinBioTherapeutics plc (AIM: SBTX, the “Company”;), a life science company focused on skin health, has passed two additional and final third party cellular toxicity tests for its SkinBiotix® technology.

The in vitro tests, for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells), follow on from the recent first stage cytotoxicity tests, as announced on 3 October 2017.

The studies were again conducted by Charles River Laboratories, a Contract Research Organisation (CRO), in accordance with the OECD Principles of Good Laboratory Practice.

In the photo-toxicity test, the testers were looking to determine whether the SkinBiotix® technology would become toxic to cells when exposed to UV and visible light. The results showed that SkinBiotix® is non-phototoxic.

The second test, for ocular toxicity, was carried out to determine whether SkinBiotix® is toxic to eye cells. This involved measuring for two important components which are predictive of irritation, corneal opacity (cloudiness) and permeability (ability to let fluids pass through the eye). The SkinBiotix® technology also passed this test.

SkinBioTherapeutics will continue developing the technology towards the three applications in skin care, anti-infection and skin repair.

Dr Catherine O’Neill, CEO of SkinBioTherapeutics, commented:

“Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy."

“With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets."

“We are continuing formulation development and are confident about starting our human studies in 2018.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

[bobalot] 11/12/2017 12:59

here is a reminder...AGAIN FOR THOSE WITH SORT MEMEORIES.



HER IS THE FIRST INTERNATIONAL PATENT --- many others will follow on very soon.


Notification of first patent grant

Manchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.

The patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company's first patent to progress to grant from within its portfolio of patents pending estate.

The patent, numbered 2013246701 and entitled 'Probiotic bacteria', runs until 15 March 2033.
The patent is in active prosecution in other locations worldwide including Europe, USA and China.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company's Skinbiotix® patent family underpins the commercial potential worldwide.
"This is a step forward in preparing for human trials, which are scheduled for 2018."

4th December, 2017

[bobalot] 11/12/2017 12:58

loads of support no problems with this stock.

[bobalot] 11/12/2017 12:54

The gains anticipated ON sbtx are far higher than anything OPTI has to offer --- not a side show a REAL PLAYER IMO....TRY SMELLING THE COFFEE.


#LoungeAct is the comedy act at least get your facts straight .

[rathean] 11/12/2017 12:44

#LoungeAct I wouldn't worry about our #bobalot, only a tiny minority of PIs will take notice of his shouty opinion pieces. Those of us in here and OPTI seem medium term capital upside, and for the very patient substantial long term gains.Bob is the comedy side-kick :)

[owenmo] 11/12/2017 11:36

Conceivably it's bobalot who's holding us back. Yes I know I "filtered" him - or thought I did - but "bad pennies" and all of that!

[bobalot] 11/12/2017 11:30

INVESTORS now have an excellent entry price that is the same as the; IPO price without the hypers....GREAT TIME AND VALUE TO ENTER SBTX imo.

owenmo =------11 Dec '17 - 11:36 - 1169 of 1169 0 0 (Filtered)

MY BAD PENNY MIGHT HAUNT YOU imo with much good fortune.

[rafboy] 11/12/2017 11:30

It seems people think that's it for news this side of Christmas, who knows if that is true?

[owenmo] 11/12/2017 11:28

Now below IPO share price for the first time. Now like it or not, that's a serious breach. Dr. Cath would do loyal shareholders a favour in releasing some Christmas cheer.

[loungeact] 11/12/2017 10:45

Never seen anyone is such emotional turmoil over a share price. Your actions are so desperate it's hilarious. Your need to ramp and flood the page with repeated information because the share price is down a little. Such a fool. DESPERATE, DESPERATE STUFF!!

[bobalot] 11/12/2017 10:32

Total tosh....go back to dreamland bokke...you are becoming a thread jester at the very least or a complete idiot....DYOR for once.


loungeact --- 11 Dec '17 - 10:45 - 1165 of 1165 1 0 (Filtered)

TROLLER IN CHIEF lol with a chest full of medals to prove it....haha

loungeact --- 11 Dec '17 - 10:45 - 1165 of 1165 2 0 (Filtered)

[bobalot] 11/12/2017 10:07

1bokke --- 11 Dec '17 - 10:03 - 1160 of 1160 0 0

I OWE NOTHING TO LIARS WHO MISLED THE OPTI MARKET --- DYOR ON THREADS AND RAMPERS..imo.

[1bokke] 11/12/2017 10:03

Bobalot, for someone who claims to only deal in facts you sure do hypothesise a lot!! You still havent answered my question Bob, who threatened you? You owe an apology.

[riskybusiness1] 11/12/2017 10:01

He thinks Opti intend to give 50% of the revenues to the supplier and that's it. Just revenue from the ingredient clearly will not make millions. Now we've heard it all.What he doesn't realise is that Skins model will be identical.

[bobalot] 11/12/2017 09:56

LETS GET THE RIGHT --- COMMERCIALISATION EARLY NEXT YEAR imo...with a major player in place already along with a major mass manufacturer already in the planning stages of production before human testing begins.

That all speaks of a high level of confidence for the tech....Dr. Cath has just been given an accolade of awards by her scientific peers for the work done...

THUS THE TECH WORKS AND WILL REACH A HUGE MARKET AT THE RIGHT PRICE.